Adaptimmune Therapeutics PLC (ADAP) Stock Rating Upgraded by BidaskClub
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
A number of other equities research analysts have also weighed in on ADAP. Cowen and Company reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research note on Tuesday, June 6th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, July 12th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics PLC currently has a consensus rating of “Hold” and a consensus target price of $12.08.
Shares of Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded down 0.76% during midday trading on Friday, hitting $5.21. The company had a trading volume of 147,611 shares. Adaptimmune Therapeutics PLC has a 12-month low of $3.76 and a 12-month high of $8.36. The firm’s 50-day moving average is $5.32 and its 200-day moving average is $5.02. The firm’s market capitalization is $487.23 million.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24). The business had revenue of $3.52 million during the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, analysts predict that Adaptimmune Therapeutics PLC will post ($1.06) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Adaptimmune Therapeutics PLC (ADAP) Stock Rating Upgraded by BidaskClub” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/25/adaptimmune-therapeutics-plc-adap-stock-rating-upgraded-by-bidaskclub.html.
Large investors have recently made changes to their positions in the stock. Creative Planning raised its stake in shares of Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock worth $223,000 after buying an additional 10,000 shares in the last quarter. Granite Investment Partners LLC bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $1,078,000. Essex Investment Management Co. LLC bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $225,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $120,000. Finally, NEA Management Company LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 21.7% in the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock worth $66,263,000 after buying an additional 2,145,000 shares in the last quarter. Institutional investors and hedge funds own 56.34% of the company’s stock.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.